Federal jury finds pharmaceutical company Gilead not guilty of patent infringement related to HIV prevention drugs

Gilead Sciences has been cleared of claims they violated patents held by the Centers for Disease Control and Prevention for a drug that prevents HIV infection.
The US government sued Gilead in 2019, arguing the company was profiting from CDC patents through sales of Truvada and Descovy, which are taken to prevent HIV.
A jury found the CDC's patents on pre-exposure prophylaxis, known as PrEP, were invalid.
Gilead's sales of Truvada and Descovy were about $2 billion in 2022.
PrEP has helped reduce new HIV infections in at-risk groups like men who have sex with men.